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A B S T R A C T
The purpose of the study was to find out differences between treatments of diabetes
type 2 after secondary oral antidiabetic drug failure. Three different methods of treat-
ment were compared: lispro insulin in combination with metformin, glimepiride and
metformin combination or two daily doses of biphasic insulin 30/70 together with bed
-time NPH insulin. The study included 87 patients with diabetes mellitus type 2 ran-
domly distributed into 3 different treatment groups. Fasting and postprandial glucose
were analyzed by enzymatic colorimetric method and HbA1c was measured by ion ex-
change chromatography. HbA1c significantly decreased in all three study groups. The
decrease was mostly expressed among patients treated with lispro and metformin. When
focused on postprandial glucose control, antihyperglycemic metformin and insulin lis-
pro therapy has greater impact on the overall metabolic control (decrease in level of
HbA1c) in comparison with the above mentioned more traditional approaches.
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Introduction
Diabetes mellitus type 2 accounts for
85% of all diabetes cases worldwide. It af-
fects approximately 5–7% of the popula-
tion in developed countries. In those
countries about 10% of the population
above 70 suffer from diabetes1,2. Based on
the United Kingdom Prospective Diabe-
tes Study and the Kumamoto study, there
is clear evidence that improved glycemic
control through intensive diabetes man-
agement alleviates and significantly post-
pones the progression of microvascular
complications in patients with diabetes
mellitus type 23–8. With the progression of
diabetes type 2, there is progressive loss
of pancreatic beta cell function and en-
dogenous insulin secretion. At this point,
most patients require exogenous insulin
therapy to achieve optimal glucose con-
trol. About 30% of diabetic patients (type
2) above the age of 30 need insulin ther-
apy. The effect of insulin treatment in di-
abetic patients (type 2) had been studied
before9. Several studies have documented
that intensive insulin therapy improves
insulin sensitivity as measured by the
glucose-insulin clamp method, besides it
decreases glucose toxicity10–13. Prolonged
hyperglycemia is known to cause impair-
ment on the level of the pancreatic beta
cells and on peripheral tissues such as
skeletal muscle3.
Three major pathophysiological abnor-
malities contribute to hyperglycemia in
diabetes type 2. These include: excessive
hepatic glucose production, impaired pan-
creatic insulin secretion and the effect of
peripheral resistance to insulin occurring
principally in liver and muscle tissue13.
Our study estimates the outcome of
different therapies in 87 type 2 diabetic
patients with respect to their metabolic
control and change in BMI during a three
-month-period of treatment based on dif-
ferent mechanisms of efficiency for each
pharmacological agent (secretion of insu-
lin, decrease of gluconeogenesis, improve-
ment of peripheral insulin resistance).
Patients and Methods
This study was carried out at the Uni-
versity Hospital »Split«, Split, Croatia,
during three months. After secondary
oral antidiabetic drug failure a total of 87
diabetic patients (type 2) were randomly
included in 1 of 3 combination regimens.
The patients were re-educated about dia-
betic diet and instructed to monitor their
blood glucose level (fasting and postpran-
dial) at least twice a day before paying
their first visit. All patients who suffered
from uncontrolled diabetes were included
in the study. Uncontrolled diabetes is de-
fined as an HbA1c value >8.5%, fasting
blood glucose values >8.9 mmol/1 in more
then 20% of all recorded glucose values
and/or glucose values >10 mol/l before
meal after maximal doses of a sulpho-
nylurea during a minimal period of three
months before starting the study. The
first group of patients were treated with
glimepiride + metformin. The second group
of patients was treated with two daily
doses of biphasic insulin 30/70 with bed-
time NPH insulin. The third group of pa-
tients was treated with a combination of
three daily doses of lispro and metformin.
The first group, treated with combination
of glimepiride and meformin, at baseline,
had BMI 32.3  3.6 kg/m2 and ages be-
tween 52 and 80 years with a mean age of
60.9  6.5 years and were diabetics 9.3 
2.5 years. This group consisted of 16 wo-
men (55.2%) and 13 men (44.8%). The
second group, treated with two daily do-
ses of biphasic insulin 30/70 and bed-time
NPH insulin, at baseline, had BMI 27.9 
3.9 kg/m2 and ages between 62 and 82
years with a mean age of 63.6  4.8 years
and were in average 10.5  3.2 years dia-
betics. This group consisted of 19 women
(65.5%) and 10 men (34.5%). The last
group, treated with combination of three
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daily doses of lispro insulin analogue and
metformin, at baseline, had BMI 30.2 
4.8 kg/m2 and ages between 46 and 70
years with a mean age of 62.3  7.2 years
and were diabetics 9.5  3.1 years. This
group consisted of 17 women (58.6%) and
12 men (41.4%).
The collected data were: age, sex and
body mass index. The glycemic profile,
defined as fasting and postprandial glu-
cose and HbA1c, was collected at the be-
ginning and after three months of treat-
ment. The fasting and postprandial glu-
cose were analyzed by the enzymatic co-
lorimetric method (Glucose GOD PAP,
Chronolab AG, Zürich, Switzerland, on
Olympus, chemistry analyzer AU 400,
Japan). HbA1c was measured by the ion
exchange chromatography method based
on separating hemoglobin adducts accor-
ding to their charge – (Chronolab AG,
Zürich, Switzerland). The data was ana-
lyzed using SPSS for Windows, version
9.0.0 1998 ® SPSS Inc.
Results
The groups did not differ in their com-
position (Table 1). The baseline value of
HbA1c was significantly different among
groups (2=6.71, p=0.035). The third
group had higher HbA1c than the others
(9.21%  1.72%; 9.21%  1.54%; 10.0% 
1.73% in groups 1, 2 and 3, respectively)
(p<0.05). Three months later the value of
HbA1c changed in all three groups (8.52%
 1.70%; 8.03%  1.05%; 8.00%  0.63% in
groups 1, 2 and 3, respectively) (p<0.05).
At the endpoint HbA1c decreased signifi-
cantly by similar values in all groups,
with no statistical significance (2=0.82,
p=0.66). The greatest fall of HbA1c was
noticed in the group treated with lispro +
metformin: –1.96 %  1.72% (Figure 1) or
in percentage terms 17.01%  17.30% (Fi-
gure 2).
We observed an improvement of fast-
ing glucose in the first and third groups,
but the most important improvement was
noticed in the group treated with lispro +
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TABLE 1











Sex Female 16 (55.2%) 19 (65.5%) 17 (58.6%) 0.67
Male 13 (44.8%) 10 (34.5%) 12 (41.4%)
BMI 32.3  3.6 27.9  3.9 30.2  4.8 0.075
Age 60.9  6.5 63.6  4.8 62.3  7.2 0.55






















beginning of study (p<0.05) after 3. months (p>0.05)
p=0.0012p=0.13 p=0.0001
Fig. 1. Results of HbA1c were assessed by
Wilcoxon matched pair test at the beginning
and after three months for each group.
metformin, but it was not significant. The
fall of fasting glucose was in the first
group –1.27  2.03 mmol/l (–10.99% 
17.17%); in the second group –0.59  3.4
mmol/l (+5.93%  52.05%) and in the
third group –2.17  2.10 mmol/l (–16.19%
 14.74%). The fall of postprandial glu-
cose from the beginning to the end of the
study was higher in the group treated
with lispro + metformin –4.31  3.4
mmol/l (–26.06%  22.05%) than in the
group treated with biphasic insulin 30/70
+ bedtime NPH 1.55  3.9 mmol/l (–5.6%
 34.7%) and in the group treated by gli-
mepiride + metformin 1.66  3.76 mmol/l
(–9.72%  36.85%). The beneficial effects
of various kinds of treatments was mostly
reflected by postprandial glucose in the
group treated with lispro + metformin (2
=10.3, p=0.006) (Figure 3 and 4).
Discussion
The objective of the study was to ana-
lyze different ways of treatment of dia-
betic patients (type 2), using our clinical
experience. There are several therapeutic
schemes available and recommended, for
the treatment of diabetic patients (type
2)14–27. The effect of peripheral resistance
to insulin and impaired pancreatic beta
cell secretion are early and primary ab-
normalities, whereas increased hepatic
glucose production is a late and second-
ary manifestation. In the early phase of
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Fig. 2. The fall of HbA1c expressed as percent
after three months treatment tested by Mann
-Whitney test for comparison between two differ-
ent groups. The greatest decrease was observed














































fall of fasting glucose after 3 months in all groups (p>0.05)
fall of postprandial glucose after 3 months in all groups (p<0.05)
p=0.0056
Fig. 3. The change of fasting and postprandial
glucose expressed in mmol/l tested by Wilcoxon
matched pairs test for comparison results at




















































































changes of postprandial glucosed (%) after three months (p<0.05)
changes of fasting glucose (%) after 3 months (p>0.05)
glimepiride+metformin biphasic +NPH lispro+metformin
p=0.87 p=0.98 p=0.0499
Fig. 4. The change of fasting and postprandial
glucose expressed as a percentage tested by Wil-
coxon matched pairs test for comparison re-
sults at the beginning and after three months
for each group separately.
disease, patients with diabetes type 2
compensate increased insulin resistance
of peripheral tissue by increasing beta
cell insulin secretion. When this compen-
sation is no longer adequate to overcome
the insulin resistance, blood glucose level
begins to rise. Over the course of the dis-
ease, insulin levels slowly begin to de-
crease and most patients with diabetes
type 2 are unable to achieve optimal gly-
cemic control with oral agents28–30. To achie-
ve optimal glycemic profile in patients
with type 2 diabetes, multiple pharmaco-
logical agents, including sulfonylureas,
meglitinides, metformin, alfa glucosidase
inhibitors, thiazolidinediones and insu-
lin, are available and can be used.
The first group of patients in the study
was treated with a combination of met-
formin and glimepiride. We preferred gli-
mepiride as a new sulphonylurea because
of the more pronounced insulin secretion
activity then glibenclamide and stronger
extra pancreatic activity29,30.
Hepatic glucose output is directly de-
creased by insulin and is indirectly inhib-
ited by the ability of insulin to reduce adi-
pose tissue lipolysis so we added bedtime
NPH insulin to the most frequent insulin
combination of two daily doses of biphasic
insulin 30/7031. Due to mentioned, we
have treated the second group of patients
with a combination of two daily doses of
biphasic insulin 30/70 and bedtime NPH.
Because of the rapid effect and shorter
duration of efficacy of insulin lispro, com-
pared to regular human insulin, the use
of insulin lispro in many clinical trials
was associated with improved control of
postprandial hyperglycaemia32–36. Today,
it is well known that postprandial hy-
perglycemia strongly co-relates with de-
veloping macro vascular complications6,7,34.
This was the reason why we selected lis-
pro insulin for the treatment of postpran-
dial hyperglycemia. The danger of increa-
sing body weight and hypoglycemic events
are eliminated by the short and rapid ef-
fect of lispro insulin. Weight gain, which
seems to be proportional to the number of
insulin injections used, can be counter-
acted by the inclusion of metformin in the
treatment regimen. Metformin offers the
advantage of not stimulating insulin se-
cretion and exacerbating hyperinsuline-
mia. The beneficial effect of adjuvant met-
formin therapy has been demonstrated in
a randomized, double blind, placebo-con-
trolled study involving 43 obese patients
with type 2 diabetes who were poorly con-
trolled with insulin36. Therefore, combi-
nation of lispro insulin and metformin re-
mains a treatment option in this patient
population.
According to a literature search (1966
–2003) there have been no clinical trials
similar to our study, which compares dif-
ferent ways of treatment diabetes type 2
based on lispro insulin and metformin ad-
ministration.
There is one report about treatment
improved by metformin and lispro insulin
administration in one 19-year-old woman
who suffered from late onset lipoatrophic
diabetes, a syndrome of extreme insulin
resistance due to acanthosis nigricans and
polycystic ovary syndrome37.
The optimal approach to glucose con-
trol at the time of sulfonylurea failure
was speculative for many authors. So,
there is examination of the impact of add-
ing preprandial lispro or metformin or
bedtime NPH insulin to glyburide33.
Data from Bastyr’s27 study suggests
that improved glycemic control can occur
when a second antihyperglycemic agent
is added, regardless of the regimen.
Conclusion
The greatest therapeutic challenge in
diabetology is defining the right time
when to include the adequate treatment
for secondary beta cell failure in type 2 di-
abetes mellitus. The therapeutical combi-
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nation of lispro and metformin provides a
better improvement in daylong glycemia,
which may account for the overall reduc-
tion in HbA1c, than combinations of gli-
mepiride and metformin and two daily
doses of biphasic insulin30/70 with bed-
time NPH insulin.
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LISPRO INZULIN I METFORMIN NASPRAM DRUGIH KOMBINACIJA
U LIJE^ENJU [E]ERNE BOLESTI TIPA 2 NAKON SEKUNDARNOG
ZATAJENJA ORALNIH ANTIDIJABETI^KH LIJEKOVA
S A @ E T A K
Cilj ovog rada je istaknuti razli~itosti u lije~enju tipa 2 {e}erne bolesti nakon sekun-
darnog zatajenja oralnih antidijabetika. U radu su ispitana tri oblika lije~enja – lispro
inzulin s metforminom, glimepirid s metforminom te dvije dnevne doze mije{anog in-
zulina 30/70 uz NPH inzulin pred spavanje. Ispitano je 87 oboljelih od {e}erne bolesti
tipa 2 koji su randomizirani u 3 grupe. Glikemija nata{te i postprandijalno je ana-
lizirana enzimatskom kolorimetrijskom metodom, a glikozilirani hemoglobin (HbA1c)
kromatografski. Sni`avanje HbA1c je bilo signifikantno u sve tri grupe, ali najvi{e kod
bolesnika lije~enih lispro inzulinom s metforminom. Antihiperglikemijsko lije~enje
kombinacijom lispro inzulina s metforminom, usmjereno na postprandijalne hipergli-
kemije utje~e na metaboli~ku kontrolu (sni`avanje HbA1c) te se pokazalo u~inkovitijim
od gore navedenih klasi~nih kombinacija.
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